The witnesses will be questioned on issues including finance for developing regenerative treatments; the most effective ways of encouraging partnership working between academics, clinicians, industry and charities; appropriate business models for commercialising regenerative research; and barriers to investment.

The evidence session will begin at 10.40 am on Tuesday 20 November in Committee Room 4 of the House of Lords.